Compare Neurocrine Biosciences Inc (NBIX) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs TORM plc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while TORM plc trades at $33.16 (market cap $3.58B). The key difference: Neurocrine Biosciences Inc is far larger — about 4.4× TORM plc's market cap, and TORM plc pays a 12.65% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TRMD | |
|---|---|---|
Market Cap | $15.77B | $3.58B |
Sector | Health | Technology |
52-Week High | $185.50 | $35.46 |
52-Week Low | $123.10 | $19.39 |
Enterprise Value | $15.78B | $4.28B |
Dividend Yield | — | 12.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
TRMD trades at $34.94, down 0.68% today, with a bullish technical signal from moving averages and strong support at $34. The company reported record Q2 2026 earnings with $3.25 EPS, though slightly missing estimates, and maintains robust profitability with a 35.52% net margin. Recent news highlights a capital increase from RSU exercises and a strong dividend of $2.40 payable in September 2026.
Outlook is positive with 100% analyst buy ratings, underpinned by strong cash flow growth and high ROE of 26.84%. Risks include reliance on volatile freight rates and potential market corrections given elevated RSI levels. The stock presents value with a low P/E of 5.75, but investors should monitor earnings consistency and global trade dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
